Tianjin Ringpu Bio Tech - Asset Resilience Ratio
Tianjin Ringpu Bio Tech (300119) has an Asset Resilience Ratio of 14.27% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 300119 working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2025)
This chart shows how Tianjin Ringpu Bio Tech's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 300119 total assets.
Liquid Assets Composition Over Time
This chart breaks down Tianjin Ringpu Bio Tech's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore 300119 strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥1.11 Billion | 14.27% |
| Total Liquid Assets | CN¥1.11 Billion | 14.27% |
Asset Resilience Insights
- Moderate Liquidity: Tianjin Ringpu Bio Tech has 14.27% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Tianjin Ringpu Bio Tech Industry Peers by Asset Resilience Ratio
Compare Tianjin Ringpu Bio Tech's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Yunnan Baiyao Group Co Ltd
SHE:000538 |
Drug Manufacturers - Specialty & Generic | 8.38% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Harbin Gloria Pharmaceuticals
SHE:002437 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Jiuzhitang Co Ltd
SHE:000989 |
Drug Manufacturers - Specialty & Generic | 7.86% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
Annual Asset Resilience Ratio for Tianjin Ringpu Bio Tech (2015–2025)
The table below shows the annual Asset Resilience Ratio data for Tianjin Ringpu Bio Tech.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 13.62% | CN¥1.04 Billion ≈ $152.58 Million |
CN¥7.66 Billion ≈ $1.12 Billion |
-4.60pp |
| 2024-12-31 | 18.22% | CN¥1.45 Billion ≈ $212.36 Million |
CN¥7.97 Billion ≈ $1.17 Billion |
-1.24pp |
| 2023-12-31 | 19.46% | CN¥1.28 Billion ≈ $187.80 Million |
CN¥6.60 Billion ≈ $965.19 Million |
-5.12pp |
| 2022-12-31 | 24.58% | CN¥1.50 Billion ≈ $219.62 Million |
CN¥6.11 Billion ≈ $893.54 Million |
+14.42pp |
| 2021-12-31 | 10.15% | CN¥577.88 Million ≈ $84.56 Million |
CN¥5.69 Billion ≈ $832.74 Million |
-0.10pp |
| 2020-12-31 | 10.25% | CN¥399.83 Million ≈ $58.51 Million |
CN¥3.90 Billion ≈ $570.58 Million |
-0.56pp |
| 2019-12-31 | 10.81% | CN¥385.29 Million ≈ $56.38 Million |
CN¥3.56 Billion ≈ $521.42 Million |
+1.57pp |
| 2018-12-31 | 9.25% | CN¥277.21 Million ≈ $40.56 Million |
CN¥3.00 Billion ≈ $438.77 Million |
+2.14pp |
| 2017-12-31 | 7.11% | CN¥207.80 Million ≈ $30.41 Million |
CN¥2.92 Billion ≈ $427.90 Million |
-2.54pp |
| 2016-12-31 | 9.64% | CN¥263.60 Million ≈ $38.57 Million |
CN¥2.73 Billion ≈ $399.95 Million |
+6.69pp |
| 2015-12-31 | 2.95% | CN¥69.30 Million ≈ $10.14 Million |
CN¥2.35 Billion ≈ $343.67 Million |
-- |
About Tianjin Ringpu Bio Tech
Tianjin Ringpu Bio-Technology Co.,Ltd. engages in the research and development, production, and sale of veterinary raw materials, pharmaceutical preparation, functional additives, and veterinary biological products. The company provides vaccines, chemical drugs, traditional Chinese medicines; feed additives, including pigs, chickens, waterfowl, cattle, sheep and pet medicines, and vaccines; and p… Read more